Ongoing treatment(s)-Biological therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy Posts on Medivizor

Rate of deep molecular response in chronic myeloid leukemia treated with nilotinib

Posted by on Apr 15, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Is reducing the dose of imatinib effective in the treatment of chronic myeloid leukemia?

Posted by on Jan 20, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of reducing the dose of imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML). Researchers found that a lower dose of imatinib can achieve the same result as a high dose in most patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to...

Read More

Can molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?

Posted by on Jan 12, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...

Read More

Evaluating the safety of ibrutinib in leukemia and lymphoma

Posted by on Oct 20, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...

Read More

CAR-T cell therapy and infection risk

Posted by on Dec 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies.  Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...

Read More

Gender affects outcomes of rituximab-based treatment

Posted by on Nov 16, 2017 in Leukemia | 0 comments

In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy.  Some background Men are more likely to develop CLL than women....

Read More